New guidelines on patient involvement in research and development

New guidelines on patient involvement in research and development

26-11-2018

Patients and patient organisations must be involved to handle the many complex ethical, legal and other issues intrinsic to the medical development process, new editorial argues.

In November, director Per Spindler from Biopeople and Professor, PhD Beatriz S. Lima from Instituto de Investigação do Medicamento (iMed.ULisboa), Lisbon, Portugal, published the editorial “The European Patients Academy on Therapeutic Innovation (EUPATI) Guidelines on Patient Involvement in Research and Development” in the journal Frontiers in Medicine.

The authors argue the added value of patient involvement and call for action to rethink the way patients and the public understand the medicines development process and their own involvement.

The authors state that there is an additional need to shape and facilitate the ways patients and patient organizations can be involved to handle the many complex ethical, legal and other issues intrinsic to the development process of the medicines and medical products. The authors believe that once armed with a deeper understanding, patients, patient experts and patient advocates will be even more empowered to work effectively with the relevant authorities, healthcare professionals and industry to influence the medicines development process for the benefit of patients and society.

Reference: Spindler P and Lima BS (2018) Editorial: The European Patients Academy on Therapeutic Innovation (EUPATI) Guidelines on Patient Involvement in Research and Development. Front. Med. 5:310. doi: 10.3389/fmed.2018.00310.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY), and it can be downloaded at: https://www.frontiersin.org/articles/10.3389/fmed.2018.00310/full?

Close
What are you looking for?
By using this website, you agree to the use of Cookies to give you the best user experience.Ok